Ozempic Side Effects: What the Trials Actually Show, From Common Nausea to Rare Risks

The Common Side Effects, With Real Numbers

Ozempic's active ingredient, semaglutide, slows stomach emptying and acts on appetite centers in the brain. The same mechanisms that reduce food intake produce its signature side effects. In STEP 1, the landmark trial of weekly semaglutide at the 2.4 mg weight-management dose, gastrointestinal events were the most frequently reported adverse events: roughly four in ten participants reported nausea at some point versus fewer than two in ten on placebo, with diarrhea, vomiting, and constipation each affecting a substantial minority [1]. Most events were mild to moderate and clustered around dose escalations.

Ozempic itself is dosed at 0.5 mg to 2 mg weekly for type 2 diabetes, lower than the Wegovy weight-management dose, and reported GI rates in its diabetes trials run lower than the STEP numbers. The pattern is the same even when the percentages differ: symptoms peak in the first weeks after starting or increasing a dose, then fade for most people.

The honest bottom line from the biggest safety dataset available: in SELECT, which followed more than 17,000 adults for over three years, adverse events led to permanent discontinuation in 16.6% of semaglutide patients versus 8.2% on placebo, driven mostly by GI symptoms [2]. Most people tolerate the drug; a meaningful minority do not.

Serious Risks: Pancreatitis, Gastroparesis, Obstruction, Gallbladder

A large claims analysis published in JAMA compared GLP-1 receptor agonist users against users of an older weight-loss drug and found elevated relative risks for three uncommon but serious outcomes: roughly a ninefold relative increase in pancreatitis, about a fourfold increase in bowel obstruction, and nearly a fourfold increase in gastroparesis (delayed stomach emptying that persists rather than resolves) [3]. Absolute risks remained low, which is the correct frame: these are rare events made somewhat less rare, not common outcomes.

Gallbladder disease deserves its own mention. Rapid weight loss from any cause raises gallstone risk, and semaglutide trials report cholelithiasis and cholecystitis more often than placebo [1][4]. Sudden right upper abdominal pain, especially after fatty meals, warrants prompt evaluation.

Kidney injury has been reported mainly as a downstream effect of severe vomiting or diarrhea causing dehydration [4]. If you cannot keep fluids down, that is a call-your-prescriber situation, not a wait-it-out situation.

The Eye Question: NAION

In 2024, a JAMA Ophthalmology study reported that patients prescribed semaglutide had a several-fold higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that damages the optic nerve and can cause permanent vision loss in one eye [5]. Follow-up studies in larger populations have produced mixed results, with some finding smaller or no elevated risk [6], and European regulators concluded in 2025 that NAION should be listed as a very rare side effect of semaglutide.

Perspective matters here: NAION is rare in absolute terms even in the elevated-risk estimates. The actionable guidance is simple. Sudden, painless vision loss or a new visual field defect in one eye is an emergency regardless of what medication you take. Report it immediately and stop guessing at causes.

The Boxed Warning and Who Should Not Take It

Semaglutide's prescribing information carries a boxed warning for thyroid C-cell tumors, based on rodent studies. Whether this translates to humans is unknown, and out of caution the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4]. A history of pancreatitis calls for individualized judgment, and the drug is not for use in pregnancy.

Hypoglycemia on semaglutide alone is uncommon because its insulin effect is glucose-dependent. The risk becomes real when it is combined with insulin or sulfonylureas, which is why those doses often come down when a GLP-1 starts [4].

Managing the Common Effects

Most GI side effects respond to mechanics rather than heroics. Eat smaller meals and stop at the first sign of fullness, since the stomach now empties slowly. Favor bland, lower-fat foods during titration weeks. Hydrate steadily. Do not rush dose increases; staying longer at a lower dose is a legitimate clinical decision, not a failure. Constipation responds to fluid, fiber, and movement before it needs medication. If symptoms are severe, persistent, or involve dehydration, weight loss you did not intend, or severe abdominal pain radiating to the back (a pancreatitis pattern), contact your prescriber rather than pushing through.

A note on "Ozempic face" and muscle loss: these are effects of rapid weight loss itself, not a specific toxicity of semaglutide. Adequate protein intake and resistance training are the evidence-aligned countermeasures during any fast weight loss.

Compounded Semaglutide Has Its Own Error Risk

Compounded semaglutide, dispensed as multi-dose vials with syringes rather than a fixed-dose pen, has generated FDA safety communications about dosing errors, including patients drawing several times the intended dose [7]. The molecule is the same; the delivery format shifts the safety burden onto measurement. If you use a compounded version, confirm the units and volume with the pharmacy in writing. Our compounded semaglutide guide covers how legitimate compounding works and what to verify.

For the full picture of how the drug works, dosing, and how it compares to Wegovy, Mounjaro, and Zepbound, see the main Ozempic guide. For the oral form, see Rybelsus. For effects shared across the whole drug class, including tirzepatide, see our GLP-1 side effects overview.